Sarepta Therapeutics, INC. (SRPT) — SEC Filings

Overview

Sarepta Therapeutics, INC. (SRPT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: On December 10, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also included information on other events and financial statements/exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31st.

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 30 neutral. The dominant filing sentiment for Sarepta Therapeutics, INC. is neutral.

Filing Type Overview

Sarepta Therapeutics, INC. (SRPT) has filed 17 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (34)

• 8-K Filing — 8-K · Dec 19, 2025
• Sarepta Therapeutics Files 8-K on Equity Sales — 8-K · Dec 11, 2025 Risk: medium
  On December 10, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also included information on
• Sarepta Therapeutics Files 8-K: Director Changes & Compensation Updates — 8-K · Dec 8, 2025 Risk: medium
  On December 7, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing the departure of a director, the election of new directors, and updates to executi
• Sarepta Swings to Q3 Loss Amid ELEVIDYS Safety Concerns — 10-Q · Nov 6, 2025 Risk: high
  Sarepta Therapeutics, Inc. reported a significant net loss of $179.9 million for the three months ended September 30, 2025, a stark contrast to the net income o
• 8-K Filing — 8-K · Nov 3, 2025
• Sarepta Therapeutics Enters Material Agreement — 8-K · Aug 29, 2025 Risk: medium
  On August 28, 2025, Sarepta Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial oblig
• Sarepta Therapeutics Reports Unregistered Equity Sales — 8-K · Aug 21, 2025 Risk: medium
  On August 18, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing indicates a transaction occurre
• Sarepta Therapeutics Announces Executive and Director Changes — 8-K · Aug 13, 2025 Risk: medium
  On August 12, 2025, Sarepta Therapeutics, Inc. announced changes in its executive and director roles. The company elected new directors and appointed new office
• Sarepta's ELEVIDYS Fuels Revenue Surge, Narrows Q2 Loss — 10-Q · Aug 6, 2025 Risk: medium
  Sarepta Therapeutics reported a significant increase in revenue for the three months ended June 30, 2025, reaching $345.2 million, up from $267.1 million in the
• Sarepta Therapeutics Files 8-K Report — 8-K · Jul 21, 2025 Risk: low
  On July 21, 2025, Sarepta Therapeutics, Inc. filed an 8-K report. The filing pertains to 'Other Events' and does not disclose specific financial transactions or
• Sarepta Acquires Roche's DMD Assets for $1.1B — 8-K · Jul 16, 2025 Risk: medium
  Sarepta Therapeutics, Inc. announced on July 14, 2025, that it has entered into a definitive agreement to acquire certain assets from Roche related to its Duche
• Sarepta Therapeutics Announces Board and Compensation Changes — 8-K · Jun 6, 2025 Risk: medium
  Sarepta Therapeutics, Inc. announced on June 5, 2025, changes in its board of directors and executive compensation arrangements. The filing also details the sub
• Sarepta Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  Sarepta Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations, including info
• Sarepta Therapeutics Files DEF 14A on Executive Compensation — DEF 14A · Apr 24, 2025 Risk: low
  Sarepta Therapeutics, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending Decem
• Sarepta Therapeutics Files 2024 10-K — 10-K · Feb 28, 2025 Risk: medium
  Sarepta Therapeutics, Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutic
• Sarepta Therapeutics Files 8-K on Financials — 8-K · Feb 26, 2025 Risk: low
  On February 26, 2025, Sarepta Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Sarepta Therapeutics Enters Material Definitive Agreement — 8-K · Feb 14, 2025 Risk: medium
  On February 13, 2025, Sarepta Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obl
• Sarepta Therapeutics Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  Sarepta Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Sarepta Therapeutics Enters Material Definitive Agreement — 8-K · Nov 26, 2024 Risk: medium
  On November 24, 2024, Sarepta Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, s
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• Sarepta Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Sarepta Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financ
• Sarepta Therapeutics Appoints New Director — 8-K · Sep 16, 2024 Risk: low
  Sarepta Therapeutics, Inc. announced on September 12, 2024, a change in its board of directors. Specifically, Dr. Richard S. Levitan has been appointed as a Cla
• Sarepta Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: medium
  Sarepta Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Delaware, operates in the pharmaceutical preparation
• Sarepta Therapeutics Appoints New CMO, Elects Directors — 8-K · Jun 7, 2024 Risk: low
  Sarepta Therapeutics, Inc. announced on June 6, 2024, the appointment of Dr. Michael L. Johnson as Chief Medical Officer and the election of Dr. Johnson and Ms.
• SC 13G/A Filing — SC 13G/A · Jun 7, 2024
• Sarepta Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 1, 2024 Risk:
  Sarepta Therapeutics, Inc. (SRPT) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Sarepta Therapeutics, Inc. filed a 10-Q for the quarter ended Mar
• Sarepta Therapeutics, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 24, 2024 Risk: low
  Sarepta Therapeutics, Inc. (SRPT) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Sarepta Therapeutics, Inc. filed a Definitive Proxy Statemen
• Sarepta Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: medium
  Sarepta Therapeutics, Inc. (SRPT) filed a Annual Report (10-K) with the SEC on February 28, 2024. Sarepta Therapeutics, Inc. filed its 2023 Form 10-K on Februar
• Janus Henderson Maintains >5% Stake in Sarepta Therapeutics — SC 13G/A · Feb 13, 2024 Risk: low
  Janus Henderson Group PLC, a major investment advisor, filed an amended SC 13G/A on February 13, 2024, indicating its continued ownership of more than 5% of Sar
• Vanguard Trims Sarepta Stake to 11.2% as of Dec 29, 2023 — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment firm, filed an amendment (SC 13G/A) on February 13, 2024, updating its ownership in Sarepta Therapeutics Inc. As of Decem
• Capital International Investors Takes 8.0% Stake in Sarepta — SC 13G · Feb 9, 2024 Risk: low
  Capital International Investors, a major investment firm, reported owning 7,377,295 shares of Sarepta Therapeutics, Inc. (SRPT) common stock as of December 29,
• BlackRock Amends Sarepta Stake, Maintains Passive Position — SC 13G/A · Jan 26, 2024
  BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating its ownership of Sarepta Therapeutics Inc. common stock as of December 31, 2023.
• Sarepta Files 8-K on Operations & Financial Condition — 8-K · Jan 8, 2024
  Sarepta Therapeutics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD d

Related Companies

ARWR · PTCT · RGNX · VYGR · RHHBY

Frequently Asked Questions